This special series on “Systemic and Targeted Therapies for Pancreas Ductal Adenocarcinoma” is edited by Dr. Colin Weekes from Massachusetts General Hospital, Boston, Massachusetts, USA.
Preclinical mouse models for immunotherapeutic and non-immunotherapeutic drug development for pancreatic ductal adenocarcinoma
The present and future of systemic and microenvironment-targeted therapy for pancreatic adenocarcinoma
The series “Systemic and Targeted Therapies for Pancreas Ductal Adenocarcinoma” was commissioned by the editorial office, Annals of Pancreatic Cancer without any sponsorship or funding. Colin Weekes served as the unpaid Guest Editors for the series.